HERBALIFE LTD.
For the period ended Aug 6, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2025 · Filed Aug 6, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Recent Developments
Recent Developments
In July, the Company announced the launch of MultiBurn — a next-generation, multi-action weight-loss supplement designed with clinically studied botanical extracts to support key areas of metabolic health*. As many consumers continue to seek pharmaceutical weight-loss solutions, the Company believes MultiBurn, with science-backed ingredients, offers an innovative, non-pharmaceutical approach. MultiBurn is available in the U.S. and will be launching in Puerto Rico in September 2025. In addition, the Company is now offering U.S. customers and preferred members the option to subscribe to automatic monthly deliveries of various products, including MultiBurn.
Also in July, at the North America Extravaganza, the Company unveiled the beta version of its new Pro2col health and wellness digital platform, referred to asPro2col Beta 1 (“1” representing the beta version). Eligible distributors who participated in the event had the opportunity to gain early access to the beta version of the app with the purchase of a 60-day supply of an early release of a healthy lifespan supplement formulated with Niagen®. The product name will be revealed at the time of the commercial launch in the U.S. and Puerto Rico, planned for the fourth quarter of 2025.
Over 7,000 distributors are engaged in this initial beta release, and the Company looks forward to gathering valuable feedback from distributors ahead of the commercial release in the U.S. and Puerto Rico planned for the fourth quarter of 2025, with additional markets to follow beginning in 2026.
“We delivered solid second-quarter results and raised our full-year net sales and adjusted EBITDA 1 guidance,” said Stephan Gratziani. “With the launch of MultiBurn™, the beta unveiling of our AI-assisted Pro2col™ app and the early release of our first healthy lifespan supplement, we’re taking bold steps that reinforce our commitment to innovation, transformative growth and long-term value creation.”
- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Second Quarter and Year to Date 2025 Key Metrics
Regional Net Sales and Foreign Exchange (“FX”) Impact
| Reported Net Sales · YoY Growth (Decline) | ||||
|---|---|---|---|---|
| $ million | Q2 ’25 | Q2 ’24 | including FX | excluding FX2 |
| North America | 272.4 | 283.2 | (3.8)% | (3.8)% |
| Latin America | 210.2 | 211.7 | (0.7)% | 9.5% |
| EMEA | 287.9 | 287.8 | 0.0% | (1.0)% |
| Asia Pacific | 408.6 | 416.7 | (1.9)% | (1.2)% |
| China | 80.0 | 81.7 | (2.1)% | (2.2)% |
| Worldwide | 1,259.1 | 1,281.1 | (1.7)% | (0.0)% |
| Reported Net Sales · YoY Growth (Decline) | ||||
|---|---|---|---|---|
| $ million | YTD ’25 | YTD ’24 | including FX | excluding FX2 |
| North America | 526.8 | 549.0 | (4.0)% | (3.9)% |
| Latin America | 416.9 | 425.9 | (2.1)% | 10.1% |
| EMEA | 561.2 | 565.7 | (0.8)% | 1.1% |
| Asia Pacific | 831.1 | 847.9 | (2.0)% | 0.2% |
| China | 144.8 | 156.9 | (7.7)% | (7.3)% |
| Worldwide | 2,480.8 | 2,545.4 | (2.5)% | 0.7% |
Outlook
Third Quarter 2025 Guidance
| $ million | Net Sales | Adjusted EBITDA1 | CapEx |
|---|---|---|---|
| Reported | +0.5% to +4.5% YoY | 150 – 160 | 20 – 30 |
| Constant Currency(a) | +0.5% to +4.5% YoY | 155 – 165 | |
| Q3 ’24 Actuals | 1,240.3 | 166.5 13.4% margin | 27.1 |
Full-Year 2025 Guidance – REVISED
| $ million | Net Sales | Adjusted EBITDA1 | CapEx |
|---|---|---|---|
| Reported | (1.0)% to +3.0% YoY | 640 – 660 | 75 – 95 |
| Previous Guidance (Apr 30 ’25) | (2.5)% to +2.5% YoY | 625 – 655 | 90 – 120 |
| Constant Currency(a) | 0.0% to +4.0% YoY | 685 – 705 | |
| Previous Guidance (Apr 30 ’25) | +0.5% to +5.5% YoY | 690 – 720 | |
| FY ’24 Actuals | 4,993.1 | 634.8 12.7% margin | 122.0 |
| (a) | Non-GAAP Measure. Represents projections using U.S. dollars at Q3 ’24 and FY ’24 average FX rates, respectively, and adjusting for other FX related impacts. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why the Company believes adjusting for the effects of foreign exchange is useful and non-GAAP guidance. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.